Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13934
Country/Region: Ethiopia
Year: 2018
Main Partner: Addis Ababa Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $3,545,678 Additional Pipeline Funding: $625,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $343,156
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $283,156
Care: Pediatric Care and Support (PDCS) $186,578
Laboratory Infrastructure (HLAB) $64,122
Strategic Information (HVSI) $50,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $611,309
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,501,045
Treatment: Pediatric Treatment (PDTX) $506,312
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 12
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 2
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 12
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 13
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 53
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 26
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 55
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 26
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 59
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 41
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 22
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 78
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 46
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 218
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 111
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 50
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 41
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 10
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 154
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 68
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 286
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 139
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 4
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 26
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 13
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 151
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 68
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 24
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 24
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 13
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 23
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 24
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 13
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 24
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 12
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 3
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 12
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 648
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 275
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 566
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 275
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 851
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 413
GEND_GBV Number of people receiving post-GBV care 2019 1,442
GEND_GBV Number of people receiving post-GBV care 2019 694
HTS_SELF 15-19, Female, Directly-Assisted 2019 67
HTS_SELF 15-19, Male, Directly-Assisted 2019 56
HTS_SELF 20-24, Female, Directly-Assisted 2019 100
HTS_SELF 20-24, Male, Directly-Assisted 2019 92
HTS_SELF 25-29, Female, Directly-Assisted 2019 103
HTS_SELF 25-29, Male, Directly-Assisted 2019 121
HTS_SELF 30-34, Female, Directly-Assisted 2019 86
HTS_SELF 30-34, Male, Directly-Assisted 2019 74
HTS_SELF 35-39, Female, Directly-Assisted 2019 86
HTS_SELF 35-39, Male, Directly-Assisted 2019 74
HTS_SELF 40-49, Female, Directly-Assisted 2019 62
HTS_SELF 40-49, Male, Directly-Assisted 2019 92
HTS_SELF 50+, Female, Directly-Assisted 2019 18
HTS_SELF 50+, Male, Directly-Assisted 2019 18
HTS_TST 15-19, Female, Negative 2019 38
HTS_TST 15-19, Male, Negative 2019 22
HTS_TST 20-24, Female, Negative 2019 133
HTS_TST 20-24, Male, Negative 2019 83
HTS_TST 25-29, Female, Negative 2019 122
HTS_TST 25-29, Female, Negative 2019 187
HTS_TST 25-29, Female, Negative 2019 283
HTS_TST 25-29, Female, Negative 2019 4,096
HTS_TST 25-29, Male, Negative 2019 138
HTS_TST 25-29, Male, Negative 2019 157
HTS_TST 25-29, Male, Negative 2019 283
HTS_TST 25-29, Male, Negative 2019 2,232
HTS_TST 30-34, Female, Negative 2019 100
HTS_TST 30-34, Female, Negative 2019 142
HTS_TST 30-34, Female, Negative 2019 283
HTS_TST 30-34, Female, Negative 2019 279
HTS_TST 30-34, Male, Negative 2019 86
HTS_TST 30-34, Male, Negative 2019 172
HTS_TST 30-34, Male, Negative 2019 283
HTS_TST 30-34, Male, Negative 2019 1,114
HTS_TST 35-39, Female, Negative 2019 1,674
HTS_TST 35-39, Female, Negative 2019 100
HTS_TST 35-39, Female, Negative 2019 142
HTS_TST 35-39, Female, Negative 2019 142
HTS_TST 35-39, Male, Negative 2019 1,393
HTS_TST 35-39, Male, Negative 2019 86
HTS_TST 35-39, Male, Negative 2019 172
HTS_TST 35-39, Male, Negative 2019 142
HTS_TST 40-49, Female, Negative 2019 1,114
HTS_TST 40-49, Female, Negative 2019 73
HTS_TST 40-49, Female, Negative 2019 376
HTS_TST 40-49, Female, Negative 2019 142
HTS_TST 40-49, Male, Negative 2019 1,393
HTS_TST 40-49, Male, Negative 2019 106
HTS_TST 40-49, Male, Negative 2019 188
HTS_TST 40-49, Male, Negative 2019 142
HTS_TST 50+, Female, Negative 2019 31
HTS_TST 50+, Male, Negative 2019 31
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 32,587
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 1,003
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 1,708
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 1,661
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 279
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 279
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 839
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 557
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 1,114
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 1,114
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 37
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 24
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 20
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 79
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 64
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 115
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 106
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 25
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 25
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 55
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 87
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 120
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 141
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 128
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 282
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 259
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 54
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 54
HTS_TST_POS 20-24, Female, Positive 2019 2
HTS_TST_POS 20-24, Male, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 3
HTS_TST_POS 25-29, Female, Positive 2019 11
HTS_TST_POS 25-29, Female, Positive 2019 260
HTS_TST_POS 25-29, Male, Positive 2019 2
HTS_TST_POS 25-29, Male, Positive 2019 3
HTS_TST_POS 25-29, Male, Positive 2019 11
HTS_TST_POS 25-29, Male, Positive 2019 139
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Female, Positive 2019 11
HTS_TST_POS 30-34, Female, Positive 2019 13
HTS_TST_POS 30-34, Male, Positive 2019 68
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 3
HTS_TST_POS 30-34, Male, Positive 2019 11
HTS_TST_POS 35-39, Female, Positive 2019 103
HTS_TST_POS 35-39, Female, Positive 2019 2
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Male, Positive 2019 88
HTS_TST_POS 35-39, Male, Positive 2019 2
HTS_TST_POS 35-39, Male, Positive 2019 3
HTS_TST_POS 40-49, Female, Positive 2019 68
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 88
HTS_TST_POS 40-49, Male, Positive 2019 2
HTS_TST_POS 40-49, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 48
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 68
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 68
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 8
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 8,239
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 8,239
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,555
PMTCT_ART Already on ART at beginning of current pregnancy 2019 808
PMTCT_ART New on ART 2019 649
PMTCT_ART New on ART 2019 420
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 2,204
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 1,228
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 2,153
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 232
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 1,733
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 56
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 3,886
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 288
PMTCT_EID Sum of Infant Age disaggregates 2019 3,886
PMTCT_EID Sum of Infant Age disaggregates 2019 288
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 5
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 2
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 6
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 11
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 2
TB_PREV By Age/Sex (Numerator): <15, Female 2019 642
TB_PREV By Age/Sex (Numerator): <15, Female 2019 17
TB_PREV By Age/Sex (Numerator): <15, Male 2019 631
TB_PREV By Age/Sex (Numerator): <15, Male 2019 17
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 5,753
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 156
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 5,766
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 156
TB_PREV IPT, Life-long ART, Already, Positive 2019 10,508
TB_PREV IPT, Life-long ART, Already, Positive 2019 279
TB_PREV IPT, Life-long ART, New, Positive 2019 2,223
TB_PREV IPT, Life-long ART, New, Positive 2019 57
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 12,777
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 346
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 12,786
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 346
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 1,610
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 17
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 734
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 17
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 4,761
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 152
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 5,641
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 152
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 10,639
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 286
TB_PREV_den IPT, Life-long ART, New, Positive 2019 2,189
TB_PREV_den IPT, Life-long ART, New, Positive 2019 59
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 140
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 16
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,370
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 161
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 140
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 16
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,761
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 209
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 3,401
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 403
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 3,428
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 404
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 138
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 16
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,355
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 161
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 138
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 16
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,779
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 209
TX_CURR 25-29, Female, Positive 2019 2,748
TX_CURR 25-29, Female, Positive 2019 552
TX_CURR 25-29, Male, Positive 2019 1,186
TX_CURR 25-29, Male, Positive 2019 233
TX_CURR 30-34, Female, Positive 2019 7,978
TX_CURR 30-34, Female, Positive 2019 1,603
TX_CURR 30-34, Male, Positive 2019 2,269
TX_CURR 30-34, Male, Positive 2019 449
TX_CURR 35-39, Female, Positive 2019 7,314
TX_CURR 35-39, Female, Positive 2019 1,470
TX_CURR 35-39, Male, Positive 2019 2,669
TX_CURR 35-39, Male, Positive 2019 537
TX_CURR 40-49, Female, Positive 2019 17,047
TX_CURR 40-49, Female, Positive 2019 3,425
TX_CURR 40-49, Male, Positive 2019 12,140
TX_CURR 40-49, Male, Positive 2019 2,381
TX_CURR Age/Sex: <1 2019 59
TX_CURR Age/Sex: <1 2019 203
TX_CURR Age/Sex: <1-9 2019 311
TX_CURR Age/Sex: 1-9 2019 2,953
TX_CURR Age/Sex: 10-14 Female 2019 1,473
TX_CURR Age/Sex: 10-14 Female 2019 203
TX_CURR Age/Sex: 10-14 Male 2019 1,474
TX_CURR Age/Sex: 10-14 Male 2019 102
TX_CURR Age/Sex: 15-19 Female 2019 2,994
TX_CURR Age/Sex: 15-19 Female 2019 603
TX_CURR Age/Sex: 15-19 Male 2019 2,412
TX_CURR Age/Sex: 15-19 Male 2019 485
TX_CURR Age/Sex: 20-24 Female 2019 3,658
TX_CURR Age/Sex: 20-24 Female 2019 734
TX_CURR Age/Sex: 20-24 Male 2019 2,475
TX_CURR Age/Sex: 20-24 Male 2019 499
TX_CURR Age/Sex: 50+ Female 2019 11,463
TX_CURR Age/Sex: 50+ Female 2019 2,308
TX_CURR Age/Sex: 50+ Male 2019 6,820
TX_CURR Age/Sex: 50+ Male 2019 1,366
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 86,487
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 17,514
TX_CURR Sum of age/sex disaggregates 2019 5,406
TX_CURR Sum of Age/Sex disaggregations 2019 1,088
TX_NEW 25-29, Female, Positive 2019 113
TX_NEW 25-29, Female, Positive 2019 28
TX_NEW 25-29, Male, Positive 2019 61
TX_NEW 25-29, Male, Positive 2019 14
TX_NEW 30-34, Female, Positive 2019 304
TX_NEW 30-34, Female, Positive 2019 94
TX_NEW 30-34, Male, Positive 2019 110
TX_NEW 30-34, Male, Positive 2019 31
TX_NEW 35-39, Female, Positive 2019 275
TX_NEW 35-39, Female, Positive 2019 84
TX_NEW 35-39, Male, Positive 2019 122
TX_NEW 35-39, Male, Positive 2019 34
TX_NEW 40-49, Female, Positive 2019 663
TX_NEW 40-49, Female, Positive 2019 199
TX_NEW 40-49, Male, Positive 2019 591
TX_NEW 40-49, Male, Positive 2019 177
TX_NEW Breastfeeding status 2019 2
TX_NEW By Age/Sex: <1 2019 5
TX_NEW By Age/Sex: <1 2019 42
TX_NEW By Age/Sex: 1-9 2019 51
TX_NEW By Age/Sex: 1-9 2019 189
TX_NEW By Age/Sex: 10-14 Female 2019 91
TX_NEW By Age/Sex: 10-14 Female 2019 291
TX_NEW By Age/Sex: 10-14 Male 2019 43
TX_NEW By Age/Sex: 10-14 Male 2019 174
TX_NEW By Age/Sex: 15-19 Female 2019 52
TX_NEW By Age/Sex: 15-19 Female 2019 12
TX_NEW By Age/Sex: 15-19 Male 2019 6
TX_NEW By Age/Sex: 15-19 Male 2019 2
TX_NEW By Age/Sex: 20-24 Female 2019 17
TX_NEW By Age/Sex: 20-24 Female 2019 3
TX_NEW By Age/Sex: 20-24 Male 2019 57
TX_NEW By Age/Sex: 20-24 Male 2019 14
TX_NEW By Age/Sex: 50+ Female 2019 251
TX_NEW By Age/Sex: 50+ Female 2019 76
TX_NEW By Age/Sex: 50+ Male 2019 168
TX_NEW By Age/Sex: 50+ Male 2019 51
TX_NEW FSW 2019 20
TX_NEW FSW 2019 9
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 2,980
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 1,012
TX_NEW Pregnancy status 2019 232
TX_NEW Pregnancy status 2019 104
TX_NEW Sum of Age/Sex disaggregates 2019 685
TX_NEW Sum of Age/Sex disaggregates 2019 623
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 76,519
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 8,477
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 1,531
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 169
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 383
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 41
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,683
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 187
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 383
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 42
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 36,953
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 4,093
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 6,500
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 721
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 2,737
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 24,718
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 488
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 4,364
TX_PVLS_den Denominator: Indication: Routine 2019 76,519
TX_PVLS_den Denominator: Indication: Routine 2019 8,477
TX_PVLS_den Denominator: Indication: Targeted 2019 48
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 245
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 253
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 5,502
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,960
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 8,964
TX_RET Numerator by Status: Breastfeeding 2019 16
TX_RET Numerator by Status: Pregnant 2019 47
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 9,684
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 265
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 279
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 5,948
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,210
TX_RET_den Denominator by Status: Breastfeeding 2019 18
TX_RET_den Denominator by Status: Pregnant 2019 51
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 49,280
TX_TB Number of ART patients who were started on TB treatment during the reporting period. 2019 615
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2019 17
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2019 15
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2019 295
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2019 288
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 1,426
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 1,424
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 23,216
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 23,215
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 33,193
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 8,301
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 2,296
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 38,860
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 4,131
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 2,305
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 459
Cross Cutting Budget Categories and Known Amounts Total: $1,590,737
Key Populations: Sex Workers $21,693
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Water $30,000
Adolescent Girls and Young Women (AGYW) $24,044
Human Resources for Health $1,500,000
Food and Nutrition: Policy, Tools, and Service Delivery $15,000